Merck Kgaa Dm 5 (MKGAF) 100.2700 $MKGAF Merck KGaA's Q1

New Post Public Reply Private Reply Replies (0) Message Board

Jun 21, 2016 at 11:08 PM

Merck Kgaa Dm 5 (MKGAF) 100.2700 $MKGAF

Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 81.22 (-2.84), PFE: 34.75 (+0.25), BMY: 71.25 (+0.29)

Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.

Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 11.61 (-0.26), BMRN: 81.22 (-2.84), PFE: 34.75 (+0.25)

Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 0.96 (-0.06), ANIP: 51.36 (-1.73), XON: 24.78 (-0.34)

Merck KGaA's Q4 Earnings Down Y/Y, Offers 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 8:20AM CST
Merck KGaA (MKGAF) reported fourth-quarter 2015 earnings of 32 cents, down 60.2% from the year over year.
GILD: 81.79 (-1.20), PFE: 34.75 (+0.25), HZNP: 16.74 (-0.06)

Merck KGaA (MKGAF) Q4 Earnings Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 3:02AM CST
Merck KGaA (MKGAF) fourth-quarter 2015 earnings per American Depositary Receipt (ADR) came in at 32 cents.

What Awaits Merck KGaA (MKGAF) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:40AM CST
Merck KGaA (MKGAF) will be reporting its fourth-quarter 2015 earnings results on Mar 8.
BDSI: 2.44 (+0.08), BMRN: 81.22 (-2.84), PFE: 34.75 (+0.25)

Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.33 (-0.06), SNDX: 11.63 (-0.92), PFE: 34.75 (+0.25)

Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 34.75 (+0.25), HZNP: 16.74 (-0.06), ARNA: 1.87 (-0.03)

Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 8.42 (-0.21), PFE: 34.75 (+0.25), ANIK: 50.17 (+0.38)

Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 8.42 (-0.21), PFE: 34.75 (+0.25), ANIK: 50.17 (+0.38)

Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 56.25 (+0.11), PFE: 34.75 (+0.25), CORT: 5.41 (-0.16)

Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 231.55 (-3.71), PFE: 34.75 (+0.25), LLY: 72.57 (-0.71)

Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 24.78 (-0.34), BXLT: 46.02 (-0.18), ANIK: 50.17 (+0.38)

Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 56.25 (+0.11), PFE: 34.75 (+0.25), CORT: 5.41 (-0.16)

Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 15.40 (-0.67), PFE: 34.75 (+0.25), CORT: 5.41 (-0.16)

BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 81.22 (-2.84), NVET: 4.51 (+0.09), REGN: 345.14 (-7.52)

Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 34.75 (+0.25), LLY: 72.57 (-0.71), NVS: 79.46 (+0.79)

Merck KGaA Continues Restructuring Efforts, Growth in Focus
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 8:40AM CDT
Merck KGaA (MKGAF) continues with its efforts to simplify the company's organizational structure and focus on the growth trajectory of the Healthcare business.
VRX: 21.64 (-0.88), PFE: 34.75 (+0.25), CORT: 5.41 (-0.16)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beta Bionics Hit with Lawsuit Over Misleading Claims

Unpacking Beta Bionics' Legal Storm Investors in Beta Bionics, Inc. —ticker BBNX—are probably feeling like they're caught in a whirlwind right now, and who can blame them? The company's facing a class action lawsuit, and the accusations aren't anything to sniff at. They're talking about violations of the Securities Exchange Act of 1934, along with some shady...

Mountain Living: Facing the Population Growth Crunch

Population Growth Reshaping U.S. Mountain Communities Living in a picturesque mountain town used to offer an idyllic escape from the hustle and bustle of city life. But now, even these scenic enclaves are feeling the squeeze from a wave of population growth that's hard to ignore. Mark Cromer tackles this head-on in his new Forum paper, 'The Long Goodnight of Rocky...

Kenneth Spells: Championing Education Leadership in 2026

Out there in Hoke County, you’ve got a man named Kenneth Spells shaking things up the way a strong leader should. Now, you know I’m not here to fluff up anyone’s feathers—especially in an arena as aching for reform as education. But credit where credit’s due, Spells picked up the ‘2026 Professional of the Year’ from The Inner Circle for a reason, and it’s...

XTI Aerospace Eyes Growth Amid Revenue Slip

A Second Quarter Snapshot Ah, the world of aerospace—where soaring ambitions often face a reality check. XTI Aerospace, hitching a ride on the drone tech boom, found itself dealing with a mixed bag this past second quarter. Coming from the streets of Miami with its quarterly numbers, XTI's interim CEO Jeremy Schneiderman is banking on drones to lift their revenue skies....

DICK'S Sporting Goods Faces Legal Challenges in Securities Suit

Trouble Brewing at DICK'S Sporting Goods Wall Street's not only about the wins. There are moments when the market throws a curveball, and right now, DICK'S Sporting Goods is facing a fast one. DJS Law Group just laid out a class action lawsuit accusing them of bending the securities law rules. It ain't pretty when a company gets tangled up in legal battles, but it's...

Meitav Tops 2025 Service Index with Stellar Growth

Meitav’s Leap to The Summit Damn, it's a wild market when a pension fund provider snatches the crown. But here we are, looking at Meitav Provident Funds and Pension Ltd., standing proudly as Israel's top dog in the 2025 Service Index for pension funds. We're talking a jump from fourth to numero uno, folks, with a hefty score of 83 out of 100. And don't sleep on their...

CAR T-Cell Therapy Offers New Hope for SPS Patients

Game-changing Developments in CAR T-Cell Therapy Leaping straight into the meat of it—our friends at the University of Colorado Anschutz are onto something big. They've wrapped up a study pushing the boundaries of CAR T-cell therapy, and let me tell you, it looks like a real game-changer for those battling the rare beast known as stiff person syndrome (SPS). Breaking...

Software Tax Hits Enterprises: Costly Control Concerns

Unanticipated Software Costs: Who's in Charge? Picture this: you're running a tech setup at a major corporation, but the software changes thrust upon you aren't anything you would've chosen freely. Yeah, that's about one in four dollars from your hot little budget spent on tweaks and adjustments you didn’t ask for. And it's not as glamorous as it sounds—more like a...

Jackson Hewitt Aims to Recruit 15,000 Seasonal Staff

Revving Up for Tax Season: Jackson Hewitt's Hiring Push When tax season looms, the hustle can't be understated, and Jackson Hewitt is cranking it up by hunting for 15,000 new recruits to tackle this annual financial circus. Starting October 26, this hiring fest is open season across the nation, pulling out all the stops to bolster its workforce. But what does this mean...

Tax Strategy Crucial: Sidnell & Webster of Lufkin Weigh In

Breaking Down Tax Prep vs. Planning Ever wonder why some folks never break a sweat come tax season, while others scramble like their hair's on fire? It all boils down to understanding two very different animals: tax preparation and tax planning. CPA veterans Yvette Sidnell and Jennifer Webster over in Lufkin, Texas, have laid it out crystal clear in their article with...